Tulane University, United States.
McKesson / US Oncology / Ontada, United States.
J Cancer Policy. 2021 Sep;29:100294. doi: 10.1016/j.jcpo.2021.100294. Epub 2021 Jul 12.
The Oncology Care Model (OCM) incentivized care coordination and cost-efficiency and has been associated with short-term care reductions, but its multi-year associations are less well-studied.
We used monthly provider-level claims data spanning nearly five years between July 1 st, 2014 and May 30th, 2019 from a large community oncology practice network where roughly half of the practices participated in the OCM. The key outcome measures were monthly mean office visits, costs, and buy-and-bill drug costs among prostate, colon, breast, and lung cancers. We conducted two quasi-experimental analyses: an event study, which measures the monthly association of providing care in an OCM relative to a non-participating practice, and a difference-in-differences model, which summarizes the event study results into post-launch average estimates. We controlled for mean differences between practices, providers, and patient.
The event study analysis shows similar pre-period estimates and trends for each cancer. The difference-in-differences estimates for office visits are statistically significant for each cancer: 33 percentage point reductions in prostate cancer (95 % CI: -0.66 to 0.00; p = 0.05), 22 percentage point reductions in colon cancer (95 % CI: -0.48 to 0.04; p = 0.09), 21 percentage point reductions in breast cancer (95 % CI: -0.45 to 0.02; p = 0.08), and 24 percentage point reductions in lung cancer (95 % CI: -0.49 to 0.00; p = 0.05). Monthly prostate cancer costs also reduced by $505 (95 % CI: -$1108 to $99; p = 0.10).
Our results suggest that the OCM was associated with relative reductions in office visits and, for prostate cancer, in overall costs too. These associations generally decreased within the first year of launch and sustained through roughly two years.
Novel payment models that incentivize care coordination and cost-efficiency like the OCM may modestly yet sustainably reduce office visits and overall costs.
肿瘤治疗模式(OCM)激励了医疗协调和成本效益,并且与短期护理减少有关,但对其多年关联的研究较少。
我们使用了从 2014 年 7 月 1 日至 2019 年 5 月 30 日近五年间来自大型社区肿瘤学实践网络的每月供应商级别的索赔数据,其中大约一半的实践参与了 OCM。主要的结果衡量标准是前列腺癌、结肠癌、乳腺癌和肺癌患者的每月平均就诊次数、费用和购买和计费药物费用。我们进行了两项准实验分析:事件研究,衡量在 OCM 中提供护理相对于非参与实践的每月关联;差异差异模型,将事件研究结果总结为发布后的平均估计值。我们控制了实践、提供者和患者之间的平均差异。
事件研究分析显示,每种癌症的前期估计和趋势相似。对于就诊次数的差异差异估计在统计学上具有显著意义:前列腺癌减少 33 个百分点(95%CI:-0.66 至 0.00;p=0.05),结肠癌减少 22 个百分点(95%CI:-0.48 至 0.04;p=0.09),乳腺癌减少 21 个百分点(95%CI:-0.45 至 0.02;p=0.08),肺癌减少 24 个百分点(95%CI:-0.49 至 0.00;p=0.05)。每月前列腺癌的成本也减少了 505 美元(95%CI:-1108 至 99;p=0.10)。
我们的结果表明,OCM 与就诊次数相对减少有关,对于前列腺癌,还与整体成本减少有关。这些关联通常在发布后的第一年就会下降,并持续大约两年。
像 OCM 这样激励医疗协调和成本效益的新型支付模式可能会适度但可持续地减少就诊次数和整体成本。